Josh Eckman

CEO

Since founding Wasatch in 2005, Mr. Eckman has been instrumental in securing funding, attracting key employees and advisors, developing strategic partnerships, designing Wasatch’s proprietary flexible manufacturing process, securing international distributorships, and building out the sales channels for current products. Mr. Eckman previously worked with the Lassonde New Venture Development Center, moving university technologies into the marketplace. Mr. Eckman graduated summa cum laude in Business Administration and Asian Studies from the University of Utah. At graduation, he was awarded the Outstanding Scholar in Business Administration and the Honors Baccalaureate Award. Mr. Eckman also received a M.S. in Mechanical Engineering (microfluidics focus) from the University of Utah.


Julian A. Abery, MSc

VP Sales & Marketing

With over 20 years of bio-industry experience, gained in both scientific and commercial roles, Julian brings a wealth of expertise in sales development and expansion for instrumentation and contract research services. Julian has strong international experience, having held senior scientific, commercial and management positions at leading biotech, instrumentation and service providers, including: Xenova Discovery Ltd (UK); Biacore AB (Sweden, now part of GE Healthcare); Amphora Discovery Corp. (USA); and multiple technology start-ups (USA & Europe) through his consultancy company. Julian earned a BSc in Clinical Biochemistry and his Master’s degree in Analytical Chemistry from the University of Greenwich, London, UK.


Yasmina Abdiche, PhD

Chief Scientific Officer (CSO)

Dr. Abdiche joined Wasatch Microfluidics as CSO in 2016 after twelve and half years’ experience in the pharmaceutical industry as a Research Fellow at Rinat-Pfizer, where she was a member of Rinat’s leadership team, served on the governing committee for Pfizer’s Post-doctoral Program, and led a group of analytical scientists that applied label-free biosensors to the discovery of therapeutic antibodies. After graduating from Oxford University in the UK with a PhD in Biological Chemistry and a Master’s degree in Chemistry, Dr. Abdiche completed post-doctoral research in Dr. David Myszka’s laboratory at the University of Utah in Salt Lake City, where she optimized biosensor methods for characterizing small molecule interactions and helped to establish carbonic anhydrase as a benchmark model system. Dr. Abdiche is co-inventor of several therapeutic antibodies in clinical trials, including TEV-48125 (formerly RN307), an anti-CGRP antibody which is currently in PhIII clinical trials for migraine, bococizumab, a PCSK9 inhibitor that was tested in PhIII clinical trials for hypercholesteremia, and RN888, a PD-1 inhibitor currently in PhI clinical trials for cancer immunotherapy.